UBS Group’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

UBS Group’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,255	Closed	-$75	–	11197
2022 Q4	$75	Buy	+1,255	New	+$45	﹤0.01%	10437
2022 Q2	–	Sell	-541	Closed	–	–	11411
2022 Q1	$0	Buy	+541	New	+$219	﹤0.01%	11292
2021 Q4	–	Sell	-1,175	Closed	-$1K	–	11034
2021 Q3	$1K	Sell	1,175 -763	-39%	-$655	﹤0.01%	9343
2021 Q2	$2K	Sell	1,938 -3,195	-62%	-$2.87K	﹤0.01%	9039
2021 Q1	$6K	Buy	+5,133	New	+$8.32K	﹤0.01%	8267

Other funds holding EUCRW

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

UBS Group's EUCRW Position: Q1 2023 in Review

UBS Group sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q1 2023, closing a stake of 1,255 shares — an estimated $75 sold.

UBS Group first reported a position in EUCRW in Q1 2021 and held it in 5 quarters. The position peaked at $6K in Q1 2021. 22 funds tracked by Wall St. Rank hold EUCRW as of Q1 2023.

UBS Group reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
UBS Group sold 1,255 Eucrates Biomedical Acquisition Corp. Warrant shares in Q1 2023, an estimated $75.
UBS Group first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 5 quarters.
UBS Group's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $6K in Q1 2021.
22 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.